Novel lipid-regulating drugs

Bibliography

• THOMPSON GR, NAOUMOVA RP: New prospects forlipid-lowering drugs. Exp. Opin. Invest. Drugs (1998) 7 (5):715–727.
   PubMedGoogle Scholar
• WOOD R, DE BACKER G, FAERGEMAN 0 et al.: Preven-tion of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Atherosclerosis (1998) 140:199–270.
   Google Scholar
• •Current European guidelines on prevention of CHD.
   Google Scholar
• BRITISH CARDIAC SOCIETY, BRITISH HYPERLIPIDAEMIA ASSOCIATION AND BRITISH HYPERTENSION SOCIETY: Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart (1998) 80 (Suppl. 2):S1–S29.
   Google Scholar
• •Current British guidelines on prevention of CHD.
   Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention ofcoronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect ofpravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl. J. Med. (1996) 335:1001–1009.
   PubMed Web of Science ®Google Scholar
• THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Preven-tion of cardiovascular events and death with pravas-tatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl. J. Med. (1998) 339:1349–1357.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA (1998) 279:1615–1622.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDYGROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandi-navian Simvastatin Survival Study (4S). Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• THOMPSON GR, BARTER PJ: Clinical lipidology at theend of the millenium. Cum Opin. LipidoL (1999) 10:521–526.
   PubMed Web of Science ®Google Scholar
• GOLDBERG RB, MELLIES MJ, SACKS FM et al.: Cardiovas-cular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation (1998) 98 (23):2513–2519.
   PubMed Web of Science ®Google Scholar
• •Evidence that diabetics benefit from pravastatin.
   Google Scholar
• HAFFNER SM, ALEXANDER CM, COOK TJ et al.: Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. (1999) 159(22):2661–2667.
   PubMed Web of Science ®Google Scholar
• •Evidence that diabetics benefit from simvastatin.
   Google Scholar
• RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N. Engl. J. Med. (1999) 341:410–418.
   PubMed Web of Science ®Google Scholar
• •Evidence that gemfibrozil is effective in secondary preven-tion of CHD.
   Google Scholar
• GOLDBERG A, ALAGONA P, JR., CAPUZZI DM et al.: Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am. J Cardiol. (2000) 85 (9) :1100–1105.
   Google Scholar
• NAKAYA N, GOTO Y: Colestilan: A new bile acids sequestrant resin. A review of its clinical study in hypercholesterolaemia in Japan. Atherosclerosis (2000) 151:134–135.
   Google Scholar
• HOMMA Y, KOBAYASHI T, YAMAGUCHI H, OZAWA H,SAKANE H, NAKAMURA H: Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in Type II hyperlipoproteinemia. Atherosclerosis (1997) 129:241–248.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH, DILLON MA, GORDON B: Colesevelamhydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastro-intestinal side effects. Arch. Intern. Med. (1999) 159(16):1893–1900.
   PubMed Web of Science ®Google Scholar
• INSULL W, MARAIS AD, ARONSON R, MANFREDA S: Fluvastatin extended-release formulation is effective in treating primary hypercholesterolaemia. Atheroscle-rosis (2000) 151 :74–75.
   Google Scholar
• KAJINAMI K, KOIZUMI J, UEDA K et al.: Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am. J. Cardiol. (2000) 85:178–183.
   PubMed Web of Science ®Google Scholar
• OLSSON AG, PEARS JS, MCKELLAR J, CAPLAN RJ, RAZA A: Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercho-lesterolaemia. Atherosclerosis (2000) 151:39.
   Google Scholar
• VAN HEEK M, FARLEY C, COMPTON D, HOOS L, ALTON K, SYBERTZ E: The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine and circulates enter ohepatically. Atherosclerosis (2000) 151:155.
   Google Scholar
• BAYS H, DREHOBL M, ROSENBLATT S et al.: low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of intestinal cholesterol absorption in 243 hypercholesterolemic subjects: Results of a dose-response study. Atherosclerosis (2000) 151:135.
   Google Scholar
• KOSOGLOU T, MEYER I, MUSIOL B et al.: Pharmacody-namic interaction between the new selective choles-terol absorption inhibitor ezetimibe and simvastatin. Atherosclerosis (2000) 151:135.
   Google Scholar
• KESANIEMI YA, ENHOLM C, MIETTINEN TA: Intestinalcholesterol absorption efficiency in man is related to apoprotein E phenotype. J. Clin. Invest. (1987) 80 :578–581.
   PubMed Web of Science ®Google Scholar
• •Data showing that rates of cholesterol absorption and synthesis are influenced by apoE phenotype.
   Google Scholar
• THOMPSON GR: Poor responders to statins: a potential target for stanol esters. Eur. Heart J. (1999) 1 (Suppl. 5) :S114–S117.
   Google Scholar
• MATSUBARA K, MATSUZAWA Y, PAO S et al.: Cholesterol-lowering effect of N-(alpha-methylbenzyl)linoleamide (Melinamide) in cholesterol-fed diabetic rats. Atherosclerosis (1988) 72 (2-3):199–204.
   PubMed Web of Science ®Google Scholar
• BURNETT JR, WILCOX LJ, TELFORD DE, KLEINSTIVER SJ, BARRETT PH, HUFF MW: Inhibition of cholesterol esterification by DuP 128 decreases hepatic apolipo-protein B secretion in viva effect of dietary fat and cholesterol. Biochim. Biophys. Acta (1998) 1393 (1) :63–79.
   PubMed Web of Science ®Google Scholar
• BOCAN TMA, KRAUSE BR, ROSEBURY WS et al.: The ACAT inhibitor Avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits. Arterio. Thromb. Vasc. Biol. (2000) 20:70–79.
   PubMed Web of Science ®Google Scholar
• BURNETT JR, WILCOX LJ, TELFORD DE et al.: Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs.' Lipid Res. (1999) 40(7):1317–1327.
   PubMed Web of Science ®Google Scholar
• OKAMOTO H, YONEMORI F, WAKITANI K, MAEDA K, SHINKAI H: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature (2000) 406:203–207.
   PubMed Web of Science ®Google Scholar
• LI AC, BROWN KK, SILVESTRE MJ et al.: Peroxisomeproliferator-activated receptor ligands inhibit development of atherosclerosis in LDL receptor- deficient mice. J Clin. Invest. (2000) 106: 523–531.
   PubMed Web of Science ®Google Scholar
• WETTERAU JR, GREGG RE, HARRITY TVV et al.: An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science (1998) 282:751–754.
   PubMed Web of Science ®Google Scholar
• •Impressive demonstration of the reduction in serum lipids achieved by an MTP inhibitor in Watanabe rabbits.
   Google Scholar
• KRIEGER M: The 'best' of cholesterols, the 'worst' of cholesterols: A tale of two receptors. Proc. NMI Acad. Sci. USA (1998) 95:4077–4080.
   PubMed Web of Science ®Google Scholar
• •Useful review of scavenger receptors.
   Google Scholar
• KOZARSKY KF, DONAHEE MH, GLICK JM, KRIEGER M, RADER DJ: Gene transfer and hepatic overexpression of the HDL receptor SR-B1 reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. (2000) 20(3):721–727.
   PubMed Web of Science ®Google Scholar
• YOUNG SG, FIELDING CJ: The ABCs of cholesterol efflux. Nature Genet. (1999) 22:316–318.
   PubMed Web of Science ®Google Scholar
• ••Review that puts into perspective the significance of therecent discovery by several groups that mutations of the ABC 1 gene cause Tangier disease.
   Google Scholar
• REPA JJ, TURLEY SD, LOBACARRO JA et al.: Regulation of absorption and ABC 1-mediated efflux of cholesterol by RXR heterodimers. Science (2000) 289:1524-1529. Gilbert R Thompsont & Rossi P Naoumova
   Google Scholar